Our drug development efforts are focused on activating System xc-, a CNS target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders.
Our lead compound, SXC-2023, is being developed to target psychiatric disorders in which glutamatergic dysfunction and oxidative stress play key roles. In addition to SXC-2023, Promentis’ pipeline includes a number of compounds that show promising activity in non-clinical studies.
SXC-2023 is an orally administered, novel small molecule designed to activate System xc-.
SXC-2023 has completed Phase 1 safety testing in healthy volunteers and is currently being assessed in two Phase 2 studies, including a Phase 2 trichotillomania study
The mechanism by which Promentis’ lead compound functions has been widely studied and validated in a number of settings.
Currently, there are no FDA-approved therapeutics designed to target System xc– for the treatment of CNS disorders, just as there are no FDA-approved therapeutics for Promentis’ first neuropsychiatric indication, trichotillomania.